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ABSTRACT: Antimalarial drugs with novel modes of action and
wide therapeutic potential are needed to pave the way for malaria
eradication. Violacein is a natural compound known for its
biological activity against cancer cells and several pathogens,
including the malaria parasite, Plasmodium falciparum (Pf). Herein,
using chemical genomic profiling (CGP), we found that violacein
affects protein homeostasis. Mechanistically, violacein binds Pf
chaperones, PfHsp90 and PfHsp70-1, compromising the latter’s
ATPase and chaperone activities. Additionally, violacein-treated
parasites exhibited increased protein unfolding and proteasomal
degradation. The uncoupling of the parasite stress response reflects
the multistage growth inhibitory effect promoted by violacein.
Despite evidence of proteotoxic stress, violacein did not inhibit global protein synthesis via UPR activationa process that is highly
dependent on chaperones, in agreement with the notion of a violacein-induced proteostasis collapse. Our data highlight the
importance of a functioning chaperone−proteasome system for parasite development and differentiation. Thus, a violacein-like small
molecule might provide a good scaffold for development of a novel probe for examining the molecular chaperone network and/or
antiplasmodial drug design.
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Malaria is one of the most prevalent human parasiticdiseases, responsible for more than 400 000 deaths in
2018.1 This disease is caused by infection with protozoans of
the genus Plasmodium, which undergo striking metabolic and
structural remodeling to support hepatic and blood infection
cycles in the mammalian host. Mammalian infection starts
with the injection of sporozoites during a blood meal of an
infected female anopheline mosquito. Sporozoites reach the
liver, where they infect hepatocytes and undergo schizogony,
generating thousands of merozoites that are then released into
the bloodstream. Within the vasculature, merozoites infect red
blood cells (RBCs), remodeling host cells during the
maturation of the parasite from early stages (rings) to mature
stages (trophozoites and schizonts). During the final stage of
schizont maturation, dozens of daughter merozoites burst
from the RBCs and invade new ones. A small percentage of
the asexual parasites differentiate into sexual gametocytes,
which are taken up by a feeding mosquito, thus continuing the
parasite’s life cycle.2 The activity of most antimalarials is
restricted to asexual blood stages.3 Very few drugs are active
against the obligatory and clinically silent liver stage of
infection or against gametocytes, the only parasitic stage
capable of transmitting malaria to the invertebrate host.4 As
such, in 2007, the Bill and Melinda Gates Foundation
prioritized the discovery of drugs for malaria prophylaxis and
transmission blocking, to underpin disease eradication.5
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Figure 1. Violacein multistage antimalarial activity. (A−C) Violacein in vitro activity against asexual stage P. falciparum 3D7 strain (A) and
chloroquine-resistant strains: Dd2 (B) and W2 (C). Graphs were calculated according with SYBRGreen measurements, and error bars represent
SEM (n = 3). (D) Violacein stage specificity within asexual parasites. Error bars represents SD (n = 3). (E) Violacein speed of action.
Asynchronous 3D7 parasites were treated with violacein for different times (24 and 48 h) to determine the EC50 fold changes in relation to the
EC50 determined at 72 h. Pyrimethamine (PYR) and dihydroartemisinin (DHA) were used as controls for slow and fast killing compounds,
respectively. The data represents one independent experiment (with internal replicates n = 3). (F) Violacein activity against stage V gametocytes;
violacein EC50 = 2.5 and 1.25 μM. The data represent the means ± SD (n = 3). (G) Anopheles aquasalis mosquitoes were fed with blood samples
collected from patients infected with P. vivax supplemented with different concentrations of violacein. Compound insecticide activity was
evaluated as the relation between dead and fed mosquitoes. The data represent the means ± SEM (n = 6). (H) Oocyst infection rates were
determined as a relation between infected and fed mosquitoes. The data represent the means ± SEM (n = 6). (I) Oocyst intensity in violacein
treated groups. Dots represent oocyst counts present in the midgut of each dissected mosquito; solid lines represent mean values of oocyst counts
found in mosquito groups fed with blood submitted to different violacein treatments. The data represent the means ± SEM (n = 6). (J)
Inhibition of P. berghei hepatic infection in vitro by violacein. Atovaquone (ATQ) was used as a positive control. The data represent the means ±
SD of triplicates (n = 1). The bars represent parasite load, assessed by the relative luminescence 48 h after infection of Huh7 cells with luciferase-
expressing P. berghei sporozoites, whereas the dots represent cell confluency.
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Cell viability relies on protein quality control processes that
ensure that essential proteins are maintained in correctly
folded, functional tertiary structures. Ensuring proteostasis in a
cellular environment, where protein concentrations can reach
>300 mg/mL,6 is a challenging task that, if unbalanced, can
lead to protein aggregation and denaturation. Cells use
molecular chaperones, powered by ATP hydrolysis, to ensure
efficient protein folding and repair.7−9 In addition to regular
cellular stresses, Plasmodium parasites have to deal with the
toxic reactive oxygen species and free heme that is released
during hemoglobin digestion.10 These parasites must also
accommodate a ∼10 °C temperature change during trans-
mission from the Anopheles mosquito to the mammalian host,
as well as the ensuing febrile episodes in the host.
Unsurprisingly, genes encoding proteins of the chaperone
system comprise ∼2% of the parasite’s genetic repertoire.11−13
Nonetheless, the parasite has only a rudimentary unfolded
protein response.14,15 Given that chaperones are essential at
multiple stages of the parasite’s life cycle,20−23 insufficiencies
in these folding machineries could be the Plasmodium Achilles’
heel.18
Over the past 200 years, natural compounds have been
exploited for malaria chemotherapy and control.20−23
Violacein is a natural compound that is produced by the
secondary metabolism of Gram-negative bacteria (e.g.,
Chromobacterium violaceum) and that exhibits broad biological
activity against cancer cells, as well as against viral, parasitic,
and bacterial microorganisms.24−26 Violacein was shown to
reduce malaria parasitemia in vivo and to provide ∼80%
protection in mice infected with a lethal strain of P. chabaudi
chabaudi.27 Despite its high activity against several pathogens,
violacein has a relatively low selectivity index (varying
between 3- and 20-fold), when comparing EC50 values
obtained against P. falciparum (Pf) and mammalian cell
cultures.25,26
Herein, we characterized the activity of violacein against the
different stages of the Plasmodium life cycle. Using chemical
genomic profiling (CGP) to elucidate its mechanism of action,
we found that violacein potentially affects the protein quality
control system, more specifically, the Hsp90/Hsp70 inter-
action network. In order to investigate the effects of violacein
on PfHsp90, structural and functional assays were performed.
In addition, although there are six members of Hsp70 proteins
in the P. falciparum genome, we selected PfHsp70-1 for all
assays, due to its soluble nature when expressed in vitro and
colocalization with its functional partner, PfHsp90.13,28,29
Thus, we provide evidence that violacein is a dual chaperone
binder that interacts with both PfHsp90 and PfHsp70-1 to
increase protein unfolding and proteasome degradation.
Additionally, the assays carried out with the Saccharomyces
cerevisiae Hsp90 and Hsp70 proteins: ScHsp82 and ScSsa1,
corroborate the idea that violacein can be capable of
influencing the functions of these molecular chaperone
families. Chaperone inhibition might shed light on violacein
antitumoral, antipathogenic, and multistage antiplasmodial
activities. The small molecule violacein may therefore provide
a good scaffold for a chaperone-specific probe and/or for
antimalarial drug design.
1. RESULTS
1.1. Violacein Exhibits Multistage Antiplasmodial
Activity. Because violacein was previously shown to reduce
parasitemia in mice infected with Plasmodium,27 we aimed to
characterize the effect of this compound against other stages
of the parasite’s life cycle. To that end, we monitored the
activity of violacein against asexual cultures of wild type
(3D7) and multidrug resistant (Dd2 and W2) P. falciparum
lines. Violacein displayed similar activity against all three
strains, with an EC50 ∼ 400 nM (Figures 1A−C and Table
S1). This finding suggests that the mechanism of action of
and/or resistance to violacein is different to that of commonly
used quinolone-based antimalarials.30−32
To determine the stage-specificity of action against asexual
blood stages, we performed pulse treatments with violacein
against highly synchronized parasite cultures at ring (young
blood stage) or trophozoite (mature blood stage) stages,
which revealed that violacein was most active against the
mature asexual blood stages (Figure 1D). We next sought to
investigate whether violacein exhibits fast or slow killing. We
treated asynchronous parasite cultures with either violacein or
control drugs known to exhibit fast (artesunate) or slow
(pyrimethamine) killing activities. Consistent with a previous
report,33 violacein exerted a fast killing mechanism, with
similar EC50 values for three different incubation times (24,
48, and 72 h) (Figure 1E).
Strategies to prevent gametocyte uptake by mosquitos or to
block parasite sexual stage development are essential to reduce
the malaria burden.34 Exposure to violacein for 48 h killed
transmission-capable (stage V) gametocytes with an EC50
value between 2.5 and 1.25 μM (Figure 1F). Furthermore,
exposure to 2.5 μM of this compound completely removed
gametocytes from the culture (data not shown).
Having shown that violacein has activity against both sexual
and asexual blood stage parasites, we next performed standard
membrane feeding assays (SMFAs) to determine the effect of
violacein on mosquito stage parasites. We performed an
SMFA whereby we exposed Anopheles aquasalis mosquitoes to
a meal of blood from patients infected with P. vivax that had
been incubated with violacein. At the minimum concentration
tested (2.5 μM), violacein exhibited substantial insecticidal
activity, killing 48% of the infected mosquitoes (Figure 1G
and Table S1). Among the surviving mosquitoes treated with
2.5 μM violacein, there was a decrease of 17% in infection,
and a significant decrease in oocyst numbers (43%) compared
to the control group (Figure 1H, I and Table S1). It is
possible that the reduction in sporogonic stages is a
consequence of the gametocydal activity of violacein.
To determine whether violacein is active against liver stage
parasites, we used a well-established luminescence-based in
vitro infection system that employs human hepatoma cells
infected with the rodent malaria parasite P. berghei.35 Due to
violacein toxicity to tumoral cells, we could not calculate the
P. berghei EC50; however we could observe that, at 1 μM of
violacein treatment, there was a reduction of hepatome
infection of nearly 50%, without impairment in the liver cell
(Figure 1J and Table S1). Furthermore, violacein affected cell
confluency at concentrations >2 μM, which might be
attributed to the antitumor properties of the compound.
Taken together, violacein demonstrated a similar dose-range
of activity against all the stages within the Plasmodium life
cycle.
1.2. Chaperone System Mutants Are Hypersensitive
to Violacein. CGP is based on the premise that diploid yeast
containing a gene expressed in heterozygosis will become
hypersensitive to sublethal doses of an inhibitor targeting the
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product of this gene49−51 (Figure 2A). This method has been
previously used to identify drug targets in Plasmodium.40
Here, we used CGP to narrow down the mechanism of
action of violacein. We cultured pools of ∼6000 barcoded
heterozygous yeast strains in the presence of violacein or
DMSO, extracted the genomic DNA, and performed deep
barcode sequencing and barcode quantification. We then
made comparisons in terms of the differential growth between
yeast pools treated with violacein EC20 or the equivalent
concentration of vehicle control (Figure 2B). Usually in
Figure 2. Violacein affects the chaperone system. (A) CGP works by comparing the growth of a pool of heterozygous diploid strains that was
treated with a compound of interest with a pool treated with vehicle control, in a way to identify possible pathways targeted by the compound of
study. As each mutant yeast strain carries a specific DNA-barcode, differential growth can be assessed by barcode sequencing. (B)
Haploinsufficiency profile of heterozygous yeast pools treated with violacein. The log fold change is plotted on the y-axis as a function of the
heterozygous yeast strains ordered alphabetically by their respective ORFs. The labels highlight the mutants that meet the condition of adjusted
p-value < 0.01 and log2 fold change < 0. The four hits labeled are yeast strains heterozygous for YGR123C (ScPpt1 protein), YGR187C (ScHgh1
protein), YPL135W (ScIsu protein), and YJR018W (dubious ORF).
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chemical genomics using S. cerevisiae, heterozygous yeast pools
are treated with EC20 concentration of a compound of interest
for 20 generations.81 In this work, we opted to treat the yeast
pools with violacein EC20 concentration for 5 and 10
generations only, in a way to avoid false positives hits. This
decision came with the onus that statistics could be
compromised, once the growth gap between yeasts with
growth defects and nonaffected mutants were not as dramatic
as they would be if they were set for 20 generations. For this
reason, to find whether the drug treatment induces a change
Figure 3. Violacein interactions with PfHsp90 and yHsp82 chaperones. (A) Structural changes in PfHsp90 and yHsp82 proteins in the presence
of an equimolar concentration of violacein, determined by far-UV CD (n = 2). (B) Thermal unfolding of PfHsp90 in the presence of violacein,
determined using DSC (n = 2). The black and red dot lines highlight the differences in the first Tm, respectively, observed for the PfHsp90
protein in the absence (Tm1 = 41.0 ± 0.2 °C) and the presence of violacein (Tm1 = 43 ± 0.2 °C) (n = 2). (C) Bar graph of the relative ATPase
activity of the PfHsp90 and yHsp82 proteins against different proportions of violacein and GA (n = 2). (D) Relative ATPase activity assays for
PfHsp90 and yHsp82 proteins as a function of GA concentrations. GA inhibited PfHsp90 and yHsp82 ATPase activity with IC50 values of 2.6 ±
0.9 and 0.6 ± 0.2 μM, respectively. Dose−response fitting performed by OriginPro 2016 software (n = 2). (E−F) Chaperone activity assays were
performed using MDH protein as a model and an equimolar concentration of violacein and PfHsp90 (E) or yHsp82 (F). Black, blue, green, and
orange symbols indicate MDH aggregation, MDH aggregation in the presence of PfHsp90 or yHsp82, MDH aggregation in the presence of
PfHsp90 or yHsp82 and violacein, MDH aggregation in the presence of PfHsp90 or yHsp82 and GA, and PfHsp90 or yHsp82 aggregation alone,
respectively. The controls of the chaperones in the presence of violacein or GA are indicated by the red and lilac symbols, respectively (n = 2).
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Figure 4. Violacein interactions with PfHsp70-1 and SSA1 chaperones. (A) Structural changes in PfHsp70-1 and SSA1 proteins in the presence
of an equimolar concentration of violacein, determined by far-UV CD (n = 2). (B) Thermal unfolding of PfHsp70-1 in the presence of violacein,
determined using DSC. The black and red dotted lines highlight the differences in the third Tm observed for the PfHsp70-1 protein respectively
in the absence (Tm3 = 85.0 + 0.1 °C) and presence of violacein (Tm3 = 83.5 + 0.1 °C) (n = 2). (C) Relative ATPase activity for PfHsp70-1 and
SSA1 proteins in the presence of different violacein concentrations. The dose−response curves illustrate the inhibition profile, obtaining IC50
values of 1.9 ± 0.8 and 4.5 ± 1.1 μM, respectively. Dose−response fitting performed by OriginPro 2016 software (n = 2). (D) Lineweaver−Burk
graphs for PfHsp70-1 and SSA1 proteins ATPase activity in the absence and in the presence of violacein suggesting noncompetitive or mixed
inhibition mechanism, abruptly changing the Vmax values and smoothly altering KM. (inset) Enzyme kinetic properties at each condition. The Vmax,
KM and kcat values for PfHsp70-1 in the absence of violacein were 1.2 ± 0.1 μM/min, 166 ± 7 μM, and 0.48 ± 0.04 1/min. The Vmax, KM, and kcat
values for the PfHsp70-1 in the presence of violacein (1:2) were 0.8 ± 0.1 μM/min, 192 ± 6 μM, and 0.32 ± 0.04 1/min, respectively. The Vmax,
KM, and kcat values for the SSA1 in the absence of violacein were 0.34 ± 0.01 μM/min, 69 ± 9 μM, and 0.14 ± 0.01 1/min. The Vmax, KM, and kcat
values for the SSA1 in the presence of violacein (1:2) were 0.29 ± 0.01 μM/min, 84 ± 8 μM, and 0.12 ± 0.01 1/min, respectively. Enzyme
kinetic properties at each condition estimated by linear fitting routine implemented by OriginPro 2016 software, accordingly to Lineweaver−Burk
equation (n = 2). (E) Chaperone activity assays were performed using MDH as a client protein model and an equimolar concentration of
violacein and PfHsp70-1. Black, blue, green, and red symbols indicate MDH aggregation, MDH aggregation in the presence of PfHsp70-1, MDH
aggregation in the presence of PfHsp70-1 and violacein, and PfHsp70-1 aggregation alone, respectively (n = 2).(F) Assays for SSA1 chaperone
activity were performed using MDH as a client protein model and different proportions of violacein. Black, blue, lilac, green, orange, gray, and red
symbols indicate MDH aggregation, MDH aggregation in the presence of SSA1, MDH aggregation in the presence of SSA1 and violacein (1:0.5),
MDH aggregation in the presence of SSA1 and violacein (1:1), MDH aggregation in the presence of SSA1 and violacein (1:2.5), MDH
aggregation in the presence of SSA1 and violacein (1:5), and SSA1 aggregation alone, respectively (n = 2).
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in yeast abundance at any time point, we used an analysis
design that included the generation as a regression variable
and and then tested using the likelihood ratio test where the
generation factor was removed in the reduced formula (see
Data and Code Availability).
The chemical genomic data did not highlight any enriched
pathway or direct target of violacein. The small number of
generations selected and the variability within replicates made
it difficult to point with confidence the results of differential
growth between vehicle and violacein treated pools. None of
the four most significantly depleted yeast strains (padj < 0.01
and Log2 Fold Change < 0), were heterozygous for genes
encoding essential proteins, but the two most significant
depleted strains were heterozygous for genes coding
chaperone related proteins: Hsp90 cochaperone protein
(Ppt1/YGR123C) and chaperone protein (Hgh1/
YGR187C), both with padj = 0.0011. Thus, we decided to
use this information as a first indication to investigate if
violacein is able to directly bind or functionally affect
representatives of the three major chaperone families in
Plasmodium: PfHsp90, PfHsp70, and PfTRiC.
1.3. Violacein Binds PfHsp90, PfHsp70-1, ScHsp82,
and ScSsa1 Molecular Chaperones. Having shown that
violacein might perturb chaperone function in yeast, we next
investigated the capacity of violacein to bind and functionally
affect PfHsp90, PfHsp70-1, and PfTRiCthree chaperones
that are essential for Plasmodium survival.13,16,17,19
The binding of small molecules to a protein can change its
circular dichroism (CD) spectrum profile due to chiral
perturbations.41,42 We thus used CD as an indicator of
violacein−chaperone protein binding. Even low doses of
violacein (1:1, PfHsp90:violacein) promoted slightly changes
in PfHsp90 CD spectra (Figure 3A), suggesting an interaction
between the two molecules. Similar findings were made for
PfHsp70-1 (Figure 3A). Moreover, additional tests performed
with the yeast Hsp90 and Hsp70 chaperones, ScHsp82
(Figure 3A) and ScSsa1 (Figure 4A) respectively, in the
presence of equimolar concentrations of violacein, also suggest
structural changes in these proteins caused by the interaction
with violacein. We then used differential scanning calorimetry
(DSC) to characterize the effects of violacein on chaperone
protein unfolding and binding energetics. We performed DSC
on full length PfHsp90 or PfHsp70-1, alone or preincubated
with violacein (Figures 3B and 4B). According to the
literature,43,44 the first PfHsp90 DSC peak corresponds to
the N-terminal domain’s melting point as it gains thermal
stability in the presence of its natural binder, ADP, increasing
the melting temperature peak 1 (Tm1) up to 6 °C higher.
Similar to ADP, violacein increased the PfHsp90 N-terminal
domain melting temperature by ∼2 °C (Figure 3B) but not
that of the C-terminal domain (second temperature
transition) (Table S2). This indicates that violacein is able
to thermally stabilize PfHsp90 nucleotide binding domain
(NBD) but not the middle domain or C-terminal domain
(PBD). The Tm1 shift induced by violacein was accompanied
by an increase in the total apparent enthalpy process (ΔH1),
meaning that the energy required to complete the unfolding of
the N-terminal domain was higher after violacein treatment.
We obtained similar results in terms of subtle structural
changes in PfHsp70-1 based on CD and DSC data (Figure 4A
and B). The DSC tests indicate that the PfHsp70-1
interaction with violacein changed the third thermal
denaturation transition (Tm3) (Table S2 and Figure 4B),
which is related to remaining structures from both Hsp70
domains45 (NBD and PBD). This observation suggests that
violacein can bind the interaction interface between the
domains.
Finally, we analyzed whether violacein is able to affect
Plasmodium CCT complex, or TRiC. A previous study
suggested that TRiC regulation is involved in parasite
resistance to the antimalarial drug, artemisinin.46 Unlike
PfHsp90 or PfHsp70-1, PfTRiC is a chaperonin complex
formed by two rings composed by eight subunits each, which
makes its expression in heterologous systems unviable. To
assess the ability of violacein to interfere with Plasmodium
TRiC, we compared the susceptibilities of knockdown
parasites for TRiC to violacein treatment with that of their
wild-type counterparts. There were no differences in the
sensitivity to violacein between the knockdown parasites, and
those expressing normal TRiC levels (Figure S1). These
results indicate that PfTRiC activity is not compromised by
violacein treatment.
In summary, our thermograph data reinforce the idea that
violacein binds the PfHsp90 N-terminal domain (NBD),
which comprises the chaperone ATP binding pocket and the
PfHsp70-1 interface between NBD and C-terminal domains.
1.4. Violacein Affects PfHsp70-1 and ScSsa1 ATPase
Activity. Because violacein is able to bind PfHsp90,
PfHsp70-1, ScHsp82, and ScSsa1 chaperones, we monitored
how violacein-mediated binding affects their ATPase activity.
Natural products, such as geldanamycin (GA) and radi-
ciol,47−49 inhibit Hsp90 by competing with the nucleotide
binding pocket at the N-terminal domain. Although there was
no change in the ATPase activity of the PfHsp90 and
ScHsp82 proteins in the presence of violacein (Figure 3C), in
the presence of GA there was an inhibition of up to 70% of
the ATPase activity of these proteins, which was also observed
for other Hsp90.48,50 The relative IC50 obtained for GA
inhibition over PfHsp90 and ScHsp82 was 2.6 ± 0.9 and 0.6
± 0.2 μM, respectively (Figure 3D).
Although our biophysical assays performed in the presence
of ADP suggested that violacein does not interfere with
nucleotide binding (Table S2), we investigated the ATP
turnover by PfHsp70-1 upon violacein treatment and used
ScSsa1 for comparative purposes. The Hsp70 ATPase activity
assays indicated a strong impairment on ATP hydrolysis
(Figure 4C), with a relative IC50 value near the 1:1 molecular
ratio of PfHsp70-1:violacein and 1:2 of ScSsa1:violacein,
suggesting that the affinity between violacein and the
plasmodial Hsp70 is greater than that of yeast, although
they share 71% identity (Figure S2). Lineweaver−Burk
(Figure 4D) and Michaelis−Menten (Figure S3) graphs of
Hsp70 proteins in the presence of violacein (1:2 proportion of
protein: compound) suggest that inhibition occurs through a
noncompetitive or mixed mechanism, with a sudden change in
the values of Vmax and mild KM (Figures 4D and S2). Thus,
while violacein binding to PfHsp70-1 does not impair
nucleotide binding, it significantly compromises ATP
hydrolysis in vitro.
Hsp70 proteins exhibit a heterotrophic bidirectional
allosteric mechanism involved in client protein binding/
releasing that is dependent on ATP hydrolysis and ADP
exchange.51 Changes in one domain may affect function of the
other chaperone domain. Indeed, previous studies have
highlighted the importance of PBD regulation for proper
Hsp70 ATP hydrolysis.52−54 In addition, the thermograms
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obtained by the DSC (Figure 4B) corroborate the idea that
violacein can bind in an interface region between the NBD
and PBD, indirectly influencing hydrolysis. Taken together,
violacein potentially disturbs the ATPase activity of Hsp70
chaperones studied here, which is essential for the functional
cycle of these chaperones.
1.5. Violacein Compromises Hsp70 Chaperone
Function in Preventing Protein Aggregation. One of
the key functions of Hsp90 and Hsp70 molecular chaperones
is to assist with protein maturation and prevent the
aggregation of misfolded protein intermediates.55 Unlike
Hsp70 proteins that have a specific region that interacts
with client substrates to prevent protein aggregation, Hsp90
Figure 5. UPR and UPS response in Plasmodium upon violacein treatment. (A) P. falciparum 3D7-GFP-DD mutant parasite design. A gene
encoding a destabilizing domain (DD) that is only stable in the presence of its ligand Shield-1, together with a GFP reporter gene (GFP) were
attached to a protein known to be degraded by the Plasmodium proteasome (Px). In the presence of Shield-1, Px acquires a stable conformation
and can be monitored by fluorescence via its GFP domain, while in the absence of Shield-1, Px gets unfolded due to the loss of the DD
conformation and is targeted to proteasome degradation. (B) GFP fluorescence signals from mutant parasites are maintained in Shield-1 for 24 h
before wash-out. Trophozoites were then treated for 3 h with compounds of interest: Shield (black), DHA (red), WR (blue), Cpd1 (purple), and
violacein (orange) and fluorescence units were recorded by flow cytometry. Concentrations of Shield-1, violacein, DHA, and cpd1 are given in
μM; WR in nM × 10. The dotted line represents background (sample fluorescence without Shield-1) (n = 3). (C) The same mutant parasites
analyzed in B were lysed, subjected to Western blotting, and probed with anti-GFP. The concentration (μM) of compound used for the samples
subjected to Western blotting is shown below the name of each compound. Anti-Bip was used as a loading control. Densitometry analysis
(ImageJ) of the ratio between αGFP/αBip (mean ± SE) is shown in the gray box (n = 3). (D) PK4 pathway activation in Plasmodium. Protein
Kinase 4 (PK4) is an ER transmembrane protein that plays a major role in Plasmodium UPR. It is proposed that under ER stress conditions,
unfolded peptides compete with PK4 for binding immunoglobulin protein (Bip) binding, causing the dissociation of Bip−PK4 interactions. Once
no longer bound to Bip, it is suggested that the N-terminal domains of PK4 dimerize, inducing the autophosphorylation of the C-terminal eIF2a
kinase domain, followed by phosphorylation eIF2a, which then leads to shut down in protein translation. (E) Western blotting against p-eIF2α.
NF54 parental line parasites were treated with different doses of violacein, DHA, or vehicle for 90 min at 37 °C, and parasite lysates were used for
Western blotting. The concentration (μM) of the compound used for Western blotting is shown below the name of each compound. Anti-eIf2α
was used as a loading control as indicated in the figure. (n = 2).
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has several binding sites for client proteins along its dimeric
structure.56 In this sense, we evaluated whether chaperone−
violacein interactions could disturb the capacity of PfHsp90,
PfHsp70-1, ScHsp82, and ScSsa1 to prevent thermally
induced aggregation of malate dehydrogenase (MDH) in vitro.
Violacein treatment did not impair the ability of PfHsp90
and ScHsp82 to prevent aggregation of MDH (Figure 3E and
F). The same was observed for Hsp90 in the presence of GA,
which suggests that the binding of this inhibitor in the Hsp90
N-terminal domain does not affect the chaperone ability to
prevent protein aggregation in vitro. A study by Kravats and
colleagues57 showed that the presence of GA interferes with
the formation of the yeast protein complex Hsp82-Ssa1-Sis1-
Sti1 and consequently decreases the efficiency in reactivation
of heat-inactivated luciferase by this protein system. These
data suggest that, although the role of PfHsp90 and ScHsp82
proteins in preventing aggregation is not impaired in the
presence of GA, refolding of client proteins assisted by Hsp90
may be affected. On the other hand, treatment with violacein
in equimolar doses impaired the chaperone function of the
PfHsp70-1 (∼70%) and ScSsa1 (∼30%) proteins, respectively
(Figure 4E, F and Table S4), showing a stronger effect on P.
falciparum Hsp70 than on the S. cerevisiae counterpart.
Moreover, the increase in the proportions of violacein resulted
in a decrease in the ability of ScSsa1 to prevent the
aggregation of MDH (Figure 4F and Table S3), which
suggests a dose-dependent action. This finding is consistent
with our earlier results showing that violacein modifies the
Hsp70-1 C-terminal domain or neighboring regions of the
PBD (Figure 4B), as Hsp70 chaperones prevent protein
aggregation by sequestering client proteins with exposed
hydrophobic regions via the PBD.55 Most Hsp70 inhibitors
interact with the NBD, impairing ATP binding.58,59 Here, we
describe a different mechanism of inhibition via the interface
region between the NBD and PBD domains, suggesting that
the interdomain communication is important for both
PfHsp70-1 ATP hydrolysis and chaperone activity.
1.6. Violacein Causes Protein Degradation via
Proteasome. The ubiquitin proteasome system (UPS) and
unfolded protein response (UPR) form two major regulatory
branches of cell stress signaling in which chaperones have a
pivotal role.15,60 To evaluate if violacein is causing protein
unfolding and/or proteasome degradation in Plasmodium, we
used mutant parasites expressing a GFP reporter linked to a
destabilizing domain (DD), which is only stable in the
presence of a binding ligand, Shield-1. In the absence of
Shield-1, the destabilized protein is turned over rapidly by the
proteasome and the fluorescence signal is decreased; while in
the presence of Shield-1, the fluorescence signal increases due
to accumulation of the GFP domain (Figure 5A).61,62
Parasites treated with violacein were compared to five control
groups treated with the following molecules: Shield1;
Compound 1 (Cpd1), a pan-inhibitor of ubiquitin-activating
enzymes (E1); dihydroartemisinin (DHA), the gold standard
antimalarial known to cause promiscuous protein damage/
unfolding and also partial inhibition of the proteasome; and
WR99210, an antifolate antimalarial that does not affect UPS
in Plasmodium. Folded proteins were detected by flow
cytometry (FC) through GFP fluorescence signals, while the
total amount of protein was obtained by Western blotting
(WB), using antibodies against GFP. As expected, in mutant
parasites treated with compounds known to impair
proteasome degradation, such as Cpd1 and DHA, proteins
are not degraded (as shown in WB data, Figure 5C).61 The
gain of GFP signaling in FC presented by cdp1 treated
parasites is consistent with accumulation of proteasome
substrate that is not recognized/degraded, as it is not
ubiquitinated. For DHA treated parasites, despite the
accumulation of mutant proteins observed by WB, the GFP
signal is below the background control line (presented by
WR99210 and nontreated parasites). This was expected as
DHA causes protein unfolding, and the lack of signaling might
be due to DHA-induced loss of GFP native conformation.
Violacein showed decreased signaling for both, GFP
fluorescence and total amount of GFP, indicating that proteins
are being unfolded and subsequently degraded by the
proteasome (Figure 5B and C).
1.7. Violacein Does Not Activate Plasmodium
Unfolded Protein Response. While in mammalian systems,
we have a robust UPR response composed by three
majoritarian arms, IRE-1, PERK, and ATF6, in Plasmodium
this response is reduced to a modified PERK pathway that
lacks transcriptional regulatory response. Under accumulation
of misfolded proteins, BiP dissociates from PK4, a trans-
membrane kinase that undergoes autophosphorylation prior to
phosphorylation of eIF2α, resulting in protein translation shut
down, in a way to avoid chaperone overload63 (Figure 5D).
Thus, we can say in that Plasmodium, eIf2-α phosphorylation
implies in decreased protein translation,63 indicating UPR
activation15,60 (Figure 5D). We investigated the profiles of
eIF2-α phosphorylation in parasites treated with violacein. As
previously reported,61 DHA treatment activates parasite UPR
by promoting shut-down in protein translation via eIF2-α
phosphorylation as a consequence of the buildup of
polyubiquitinated proteins. Violacein treatment did not result
in eIF2α phosphorylation (Figure 5E), suggesting that protein
synthesis is not hampered by UPR activation (for biological
replicate see Figure S4). Altogether, this data indicates that
violacein is not causing accumulation of unfolded proteins in
Plasmodium parasites, which is in accordance with our
previous data showing that misfolded proteins are likely
being degraded by the proteasome (Figure 5B and C).
2. DISCUSSION
Violacein is a naturally occurring small molecule that has the
ability to control malaria in mice.27 There are hundreds of
studies reporting the activity against different organisms and
models, such as bacteria, viruses, and cancer cells. In this
work, we tested violacein activity against three different
Plasmodium species in a way to cover the life cycle of
Plasmodium spp. We used the widespread P. berghei murine
model, to evaluate the activity of violacein against liver stage
parasites. Using P. berghei as a model has some advantages
over P. falciparum when performing drug screening against
hepatic stages, as it poses lower biosafety risks, generates more
sporozoites, has a shorter cycle within hepatocytes, and can
easily infect hepatoma cell lines.64 P. vivax and P. falciparum
are the major Plasmodium species responsible for malaria
burden in humans, thus the principal targets for therapeutic
intervention. Due to the lack of a continuous in vitro
culture,65 usually P. vivax is excluded from the malarial drug
discovery pipeline, which is focused mainly in P. falciparum.
Here, we performed a standard membrane feeding assay
(SMFA) using P. vivax field isolates to evaluate if violacein
impairs transmission in this model. Finding compounds that
are able to block P. vivax transmission has an epidemiologic
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importance in P. vivax control, once one of the main reasons
that underlies the difficulty in blocking P. vivax transmission
happens due to its ability to produce gametocytes at the very
beginning of infection, contributing to high transmission
rates.66
To guide our investigations on the mode of action of
violacein, we performed yeast-based chemical genomic
profiling, an assay that allows us to identify from a pool of
mutants, the heterozygous yeast strains that are most sensitive
to violacein, giving us a clue about possible targets or
biochemical pathways affected by the compound. Although we
did not obtain clear targeted pathways or proteins in our CGP
screen, the fact that two out of four hits are involved in
chaperone processes made us hypothesize that violacein might
be interfering with the chaperone system. Thus, we decided to
investigate whether violacein could indeed be affecting this
protein quality control network by investigating the
interaction of violacein with the yeast Hsp90 and Hsp70
chaperones, (ScHsp82 and ScSsa1, respectively) and with the
three major components of the parasite’s chaperone system:
PfHsp90, PfTRiC, and PfHsp70-1.
We found that violacein binds the two most abundant
chaperones in Plasmodium, PfHsp90 and PfHsp70-1,12 which
are known to be active in proteostasis when they work
together.28,67 We found no evidence of an interaction of
violacein with PfTRiC. Although violacein treatment does not
interfere with the ATPase activity of PfHsp90, it impairs
PfHsp70-1 ATP hydrolysis. In addition to compromising
nucleotide exchange, violacein binding to the PfHsp70-1
PBD/NBD inhibits its chaperone function in vitro. Violacein
was also shown to bind the yeast functional partners ScHsp82
and ScSsa1,57 inhibit the ATPase activity of ScSsa1 and to
impair its chaperone activity in a similar fashion as it does for
the Plasmodium ortholog, PfHsp70-1.
A recent study showed that violacein induces aggregation of
actin in Plasmodium without affecting actin polymerization.68
The study suggests that violacein might be interacting with
actin indirectly via actin binding partners or by disturbing
actin folding pathway. We propose that violacein disrupts the
Plasmodium foldosome, in which Hsp70 and Hsp90 are critical
players for the survaillance of protein folding, trafficking,
quality control, and degradation processes.
To investigate if violacein affects the ubiquitin proteasome
system in Plasmodium, we usedP. falciparum parasites
transfected with plasmids containing a modified PfFKBP
gene, which codes a protein known to be quickly degraded by
the proteasome attached to a destabilizing domain (DD)
(only stable in the presence of its ligand Shield-1) and a GFP
reporter gene. Although we did not performed a direct assay
showing violacein interaction with proteasome, the diminished
values of GFP signaling and total amount of protein, observed
by both, FC and WB, supports the idea that violacein does not
impair proteasomal degradation, as the experiment suggests
that violacein causes protein unfolding followed by intense
protein degradation via proteasome. Because UPR in
Plasmodium is triggered by accumulation of unfolded proteins,
it is not surprising that, in violacein treated parasites, this
branch of the stress response is not activated (no
phosphorylation of eIf2-α). Thus, these experiments suggest
that violacein is causing protein unfolding/degradation, but
protein synthesis does not seem to be discontinued as a result
of UPR stress response activation. In summary, our data
indicates that the system for attenuating protein synthesis is
not disrupted, permitting ongoing protein synthesis. However,
protein synthesis itself is an error-prone process that heavily
relies on chaperones to succeed, supporting violacein-induced
collapse of proteostasis (Figure 6).
Importantly, the results presented here do not sustain the
idea that the Hsp90/70 network is the only target of violacein.
It is possible that violacein is a promiscuous compound that
causes protein damage as a whole, and the loss of function of
the chaperone network reinforces the proteostasis collapse
causing cellular death.
Chaperones were first proposed as drug targets in the early
1990s, for cancer therapeutics. Two decades later, there were
already 17 inhibitors at clinical trials, making chaperones one
of the most pursuit targets for oncological treatment in earlier
21st century.69 Nonetheless, clinical use of these molecules
have been hampered by toxicity.70 As is the case for
proteasome inhibitors, chaperone inhibitors might face
obstacles regarding compound selectivity for the parasite
Figure 6. Proposed mechanism for violacein mode-of-action in
Plasmodium. Violacein promotes PfHsp70-1 inhibition with possible
impairment on PfHsp90 chaperone activity, preventing folding of
damaged and newly synthesized peptides. Chaperone overburden
shifts its function toward proteolytic pathways, culminating in protein
polyubiquitination and intense proteasome degradation that leads to
imbalanced proteostasis, causing parasite death. Despite intense
proteolysis, protein synthesis continues, possibly in an attempt to
compensate for the loss of essential proteins by the proteasome,
reinforcing violacein-induced proteostasis collapse.
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target, due to high rates of conservation of chaperones. Going
forward, as violacein potential to bind PfHsp70-1’s interface
between NBD and PBD, a variable domain within human and
parasite chaperones, makes it a scaffold to be considered for
future probe for molecular chaperone network or/and
antiplasmodial drug design approaches. We anticipate that
due to the high degree of protein conservation, chaperone
inhibition might shed light on antitumoral, antipathogenic,
and multistage antiplasmodial activities of violacein.
3. CONCLUSION
Despite advances in understanding of evolution, genetics, and
proteomics of different organisms, our comprehension on how
small molecules evolved to control these processes falls short.
Natural products are an important source of therapeutic
chemical scaffolds and, historically, have played an important
role in malaria chemotherapy. Here we show that the naturally
occurring molecule, violacein, is able to bind the functional
partners, Hsp90 and Hsp70-1, the two most abundant P.
falciparum chaperones. This binding compromises the ATPase
activity of PfHsp70-1 and the chaperone function in
preventing protein aggregation is greatly impaired in vitro.
Inhibition of the chaperone system is consistent with observed
changes in protein folding and proteasome degradation in
violacein-treated P. falciparum and might underline the
multistage antiplasmodial properties of violacein. The use of
unbiased methods for target fishing in P. falciparum, such as
genome-wide thermal proteome profiling or genomic analysis
of violacein-resistant lines, are important for further validation
of the present findings.
4. METHODS
4.1. Experimental Models. 4.1.2. P. falciparum Cultur-
ing. The P. falciparum chloroquine-sensitive strains (3D7),
multidrug resistant strains (W2 and Dd2), and the mutant
strain, GFP-DD, used in this study were cultured at 4%
hematocrit in type O+ human red blood cells (Hematology
Center of University of Campinas) and maintained at 37 °C
in an atmosphere containing 1% O2, 5% CO2, and 94% N2, in
RPMI medium supplemented with 10% pooled human serum
(Hematology Center of University of Campinas).71
4.1.3. Huh7 Cell Culturing. Huh7 cells were routinely
cultured in RPMI 1640 medium supplemented with 10% (v/
v) fetal bovine serum, 1% (v/v) glutamine, 1% (v/v)
penicillin/streptomycin, 1% (v/v) nonessential amino acids,
and 10 mM HEPES, and incubated at 37 °C in a humidified
atmosphere containing 5% CO2.
4.1.4. Mosquito Rearing and Parasite Production. All
animal experiments were performed in strict compliance with
the guidelines of the animal ethics committee of Instituto de
Medicina Molecular Joaõ Lobo Antunes (iMM JLA, Lisboa,
Portugal) and the Federation of European Laboratory Animal
Science Associations (FELASA). Animals were purchased
from Charles River Laboratories and kept under specific
pathogen-free conditions in iMM JLA’s animal facility.
BALB/c mice were infected by intraperitoneal (i.p.)
injection of RBCs infected with luciferase (Luc)-expressing
P. berghei ANKA parasites.72 Female Anopheles stephensi
mosquitoes, reared at iMM JLA, were fed on the infected
mice for sporozoite production. Following infection, mosqui-
toes were maintained at 20 °C and 80% humidity and were
fed on 5% (w/v) glucose and 0.05% (w/v) PABA solution.
4.1.5. Patient Blood Samples. Blood samples were
collected from six individuals infected with P. vivax (with
parasitemia ≥2%). All participants provided a signed Informed
Consent Form. The project was approved by the Research
Ethics Committee (no. 2.584969 of April 6, 2018). Patient
blood (∼5 mL) was collected by venipuncture, and the
samples were placed into a sterile heparinized vacutainer tube
in the Fundaca̧õ de Medicina Tropical Doutor Heitor Vieira
Dourado (FMT-HVD) (Manaus, Amazonas, Brazil).
4.1.6. Anopheles aquasalis Maintenance. Anopheles
aquasalis were reared at the insectaries of the Laboratory of
Medical Entomology at the FMT-HVD. Colonies were kept at
a 24−26 °C and a relative humidity of 70−80% on a 12:12
light−dark cycle. Larvae were hatched at room temperature, in
water containing salt at a final concentration of 2 g/L, and
ground fish food (Tetramin Gold) was provided daily. Larvae
were allowed to pupate and become adults in an enclosed
mesh-covered cage with water and fed ad libitum with a 10%
sucrose solution until 2 d before being given the infective
blood meal.73
4.1.7. Yeast Cultures. Wild type yeast (BY4743) was
cultured in complete YPD (1% w/v yeast extract; 2% w/v
peptone; 2% w/v glucose) at 30 °C and 200 rpm.
Heterozygous mutant yeast pool was maintained and cultured
in complete YNB (YNB drop-out minus uracil; 2% w/v
glucose, 2% uracil) at 30 °C and 200 rpm.
4.2. Methods Details. 4.2.1. Chemicals. Violacein was
purchased from Sigma-Aldrich (Janthinobacterium lividum
V9389) or produced in an E. coli heterologous system.25 The
compound obtained from either source has a minimum purity
of 85%.
4.2.2. Inhibitory Concentration Assay against P. falcipa-
rum Asexual Stages. Drug inhibition assays were performed
as previously described.74 Briefly, D-sorbitol synchronized ring
cultures (0.5% parasitemia and 2% hematocrit) were plated in
96-well plates in the presence of different concentrations of
violacein or of the drug vehicle (DMSO), as a control. After
72 h of incubation, parasitemia was assessed by fluorometry
using SybrGreen (see table of resources) fluorescent dye. EC50
values were calculated by plotting Log dosing vs growth
inhibition (expressed as percentage relative to the drug-free
control).
4.2.3. Violacein Stage Specificity within P. falciparum
Asexual Parasites. Hyper-synchronized 3D7 schizonts were
enriched by incubating the parasite culture with two rounds of
5% sorbitol followed by 65% Percoll purification. Schizonts
were collected and reincubated for 3 h to allow merozoite
egress and reinvasion. After incubation for 0−3 h or 20−23 h,
the parasite culture was again sorbitol-synchronized for early
ring or trophozoite stage purification. Highly synchronized
ring-stage parasites were plated in a 96-well plate following the
same adjustments and treatments as described in section 4.2.2.
For ring stage susceptibility, parasites purified 0−3 h
postinvasion were incubated with the indicated compounds
of interest for 18 h. For trophozoite stage susceptibility,
parasites purified 20−23 h postinvasion were treated with the
indicated compounds of interest and controls for 18 h.
Parasitemia and EC50 values were calculated as described in
section 4.2.2.
4.2.4. Violacein Speed of Action. The speed of violacein
action was evaluated as previously described.33 Briefly, parasite
growth was evaluated departing from an asynchronous culture
in the presence of violacein and control antimalarial
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compounds: artesunate (quick action) and pyrimethamine
(slow action).33 P. falciparum 3D7 parasites were incubated in
the same conditions as described in 5.2..2, with the exception
that the parasites were treated for 24, 48, and 72 h (the
standard time for this assay) with the compounds of interest
and subsequently frozen for 24 h at −20 °C. Data were
acquired by fluorometry according to the SybrGreen protocol,
as described in in section 4.2.2.
4.2.5. Violacein Activity against Hepatic Infection by P.
berghei. Hepatic stage susceptibility assays were performed as
previously described.72 Briefly, Huh7 cells were seeded on a
96-well plate at 1 × 104 cells/well in 100 μL of culture
medium, RPMI medium supplemented as described in in
section 4.2, and incubated overnight at 37 °C in a humidified
atmosphere containing 5% CO2. The cells were then
incubated with vehicle drug control (DMSO) or with different
concentrations of violacein diluted in infection medium, i.e.
culture medium supplemented with gentamicin (50 μg/mL)
and amphotericin B (0.8 μg/mL), in triplicate wells. Firefly
luciferase-expressing P. berghei sporozoites were obtained from
dissected salivary glands of infected female Anopheles stephensi
mosquitoes. Then, 1 × 104 sporozoites were added to which
well, and the plates were centrifuged for 5 min at 1800g prior
to incubation for 46 h at 37 °C in 5% CO2.
Compound cytotoxicity was assessed by measuring cell
confluency. Here, the culture medium was removed from the
plate and 80 μL of a 1:20 solution of AlamarBlue prepared in
complete RPMI medium was added to each well and
incubated for 1.5 h at 37 °C in 5% CO2. Fluorescence was
measured on a plate reader at 530 nm excitation and 590 nm
emission wavelengths. Infection rates were assessed by
luminescence reading following cell lysis and addition of the
luciferin substrate (Biotium, USA). Briefly, the AlamarBlue
solution was removed and each well was washed with PBS.
Then, cell lysis buffer (70 μL/well) was added to each well
and incubated for 15 min at room temperature, with shaking
at 600 rpm. The plates were then centrifuged for 5 min at
1800g to remove the cell debris/membranes, and 30 μL of the
lysed supernatant was transferred to a 96-well nucleon flat
white plate, followed by the subsequent addition of 50 μL/
well luciferin solution.
4.2.6. Violacein Activity against P. falciparum Game-
tocytes. The high producing gametocyte NF54-Luc strain was
cultured following standard culture procedures, as described in
in section 4.2. Gametocytes were produced as previously
described.75,76 Briefly, parasites were cultured until they
reached 8−10% parasitemia at trophozoite stages. Parasite
culture containing spent medium was resuspended and
transferred to a T-175 flask containing complete parasite
medium (3/4 volume of the culture), and hematocrit was
adjusted to 5%. The culture was maintained for 10 days in the
presence of 62.5 mM N-acetyl glucosamine to inhibit
merozoite invasion and thus asexual replication. The medium
was changed daily without addition of RBCs. To evaluate
whether violacein can affect gametocyte stage V viability, stage
V NF54-Luc gametocytes were magnet-purified and treated
with violacein for 48 h at 2% gametocytemia and 1.5%
hematocrit in a gas chamber at 37 °C prior to luciferase
activity measurements. Luciferase activity was determined in
20 μL parasite lysates by adding 50 μM of luciferin substrate
(Promega Luciferase Assay System) at room temperature
(RT) and detection of resultant bioluminescence at an
integration constant of 10 s with the GloMax-Multi+
Detection System with Instinct Software.
4.2.7. Anopheles aquasalis Oocyst Density Evaluation by
Standard Membrane-Feeding Assay (SMFA). For An.
aquasalis infection, blood from P. vivax-infected patients was
centrifuged at 500g and resuspended in 40% hematocrit with
AB+ plasma and violacein or vehicle control (DMSO) was
added. Mosquitoes were divided into experimental groups
(violacein in 2,5, 5, and 10 μM diluted in DMSO) and a
control group (blood plus 0.1% DMSO) and exposed for 2 h
to a blood meal. Seven days postinfection, the midguts were
dissected in PBS, placed on a glass slide, and stained with
0.1% commercial Mercurochrome (Merbromin, Saint Louis,
USA). The infection rate (percentage of infected midguts)
and the infection intensity (mean number of oocysts/midgut)
on each mosquito were recorded and compared.
4.2.8. CGP Using the Yeast Model. A collection of ∼6000
yeast strains was collected, where one copy of each of the
predicted S. cerevisiae open reading frames (ORFs) was
replaced by an antibiotic resistance marker (KANMX4). Each
cassette was flanked by 20-bp DNA barcode sequences unique
to each of the deleted ORFs, as described previously.36−39,77,78
These barcodes were flanked by sequences allowing
amplification of all “uptags” and “downtags” by common
primer pairs. The violacein EC20 was determined for wild-type
yeast (BY4743), as previously described.79 The heterozygous
yeast pool collection was distributed in 500 μL YNB complete
medium in triplicates, either with violacein EC20 or vehicle
control in 48-well plates kept at 30 °C with agitation at 200
rpm. A fraction (1/20) of the culture was diluted in a new
plate every 12 h for 24 h (5 and 10 yeast generations).
Cultures were harvested by centrifugation and were
resuspended on TE buffer and stored at −80 °C until further
use.
Genomic DNA was extracted using a Wizard Genomic
DNA Purification Kit (Promega), according to the manu-
facturer’s conditions. Purified genomic DNA was sent for
barcode sequencing at the Centro de Sequenciamento
Genômico da Universidade de Saõ Paulo/ESALQ. Data
obtained from Illumina sequencing (100 bp paired-end
reads) were subsequently processed for barcode quantifica-
tion. Briefly, the DESeq2 package (version 1.30.0) was used to
normalize the barcodes counts and to estimate the differential
abundance between treated samples and their respective
controls.80 A filter was further established to remove the
barcodes with a low count along the samples (<10
observations in six samples). Differentially depleted barcodes
were identified using a maximum likelihood ratio test (LRT),
which consists of a generalized linear model in which the
number of observations of a given barcode is described by a
negative binomial distribution whose average is given by the
treatment. Normalization between samples was achieved by
library size factor method, using only amplicon sequence
variants (ASVs) with the number of observations > 0. We
considered significant hits strains that presented an adjusted p-
value < 0.01 and log2 fold change < 0 (growth defect). For
more information and details for code reproducibility, please
see Data and Code Availability.
4.2.9. Cell Lysate Analysis by Western Blotting. Protein
lysates for Western blotting were prepared from a Pf 3D7
culture of 5% trophozoite at 5% hematocrit treated with
different concentrations of compounds, as indicated in the
figure legends, for 3 h at 37 °C, as previously described.61,62
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For experiments using GFP-DD mutant parasites, 5%
trophozoite culture at 5% hematocrit was subjected to
different compound treatments for 3 h. Parasites were then
isolated with 0.05% (w/v) saponin and the pellet was washed
three times with PBS supplemented with an EDTA-free
protease inhibitor cocktail (Roche). Parasite pellets were next
solubilized in SDS-PAGE loading buffer and separated on a
4−12% Bis-Tris acrylamide gel (Life-Technologies) using
MES or MOPS running buffer and transferred to a
nitrocellulose membrane (iBlot; Life Technologies).61. After
blocking, the membranes were probed overnight at 4 °C with
the following primary antibodies:mouse anti-GFP (Roche;
1:1000), mouse anti-Pf-BiP (1:1000), rabbit antiphospho-
eIF2-α (Cell signaling Technology; 1:1000). After washing
with TBS-T, the membranes were probed with the following
secondary antibodies: goat antirabbit IgG-peroxidase (Sigma-
Aldrich-A0545; 1:20.000) and goat antimouse IgG-peroxidase
(Chemicon-AP127P; 1:20.000). The membranes were then
washed with TBS-T and incubated with enhanced chem-
iluminescent (ECL) reagents (Bio-Rad), prior to chemilumi-
nescence detection employing a Bio-Rad ChemiDoc MP
imaging system.
4.2.10. GFP Fluorescence Measurement Using Flow
Cytometry. Cultures of GFP-DD mutant parasites with 5%
trophozoite at 5% hematocrit were exposed to the indicated
drug treatments for 3 h. Parasite samples were stained with 2
μM SYTO-61 for 20 min and adjusted to 0.1% hematocrit in
PBS for plate reading using a FACSCantoTM II cytometer
(Becton Dickinson). The data were analyzed using FlowJo
(version 10) software, with the parasites gated based on the
SYTO-61 signal. The GFP fluorescence of the parasites was
reported as the fluorescence values. Data were fit by nonlinear
regression and plotted using GraphPad Prism software.
4.2.11. Recombinant Protein Expression, Purification and
Bioinformatics Analys is . Recombinant Pf Hsp90
(XP_001348998.1), PfHsp70-1 (XP_001349336), and
ScHsp82 (NP_015084.1) proteins were expressed by the
expression vector pET28a::PfHsp90, pET28a::PfHsp70-1,
and pProEx-HTa::ScHsp82 (a gift from Prof. Walid A.
Houry, University of Toronto, CA) obtained from a previous
study and purified until homogeneity, as previously
described.82,83 Recombinant ScSsa1 (NP_009396.2) was
expressed by the expression vector pET28aTEV:ScSsa1 (a
gift from Prof. Carlos H. Inaćio Ramos, University of
Campinas, SP, Brazil) in the E. coli Bl21 (DE3) strain
grown in LB medium containing 35 μg/mL of kanamycin (up
to OD600 = 0.6−0.8) at 37 °C and 200 rpm. Induction was
performed using 0.4 mM IPTG, with incubation at 20 °C and
200 rpm for 18 h. After induction, the cells were centrifuged,
disrupted in the presence of 1 mM PMSF and the
recombinant ScSsa1 protein was purified as described for
PfHsp70-1.82 The purity of all steps was assessed by 12%
SDS-PAGE, and the His-tag on the recombinant proteins was
kept. The amino acid sequences of the PfHsp70-1 and ScSsa1
proteins were aligned and the identity between them was
obtained using the Clustal Omega program (www.ebi.ac.uk/
Tools/msa/clustalo/).
4.2.12. Circular Dichroism (CD) for Analysis of Pf Hsp90−
Violacein and Pf Hsp70-1−Violacein interactions. CD
spectropolarimetry experiments were performed using a
Jasco J-815 spectropolarimeter (Jasco, Inc.), under temper-
ature control by a Peltier system. The far-UV CD was
performed in a 1 mm quartz cuvette with a 0.2 mm path
length using a buffer composed of 40 mM HEPES-KCl (pH
7.5) and 100 mM KCl for PfHsp90 and ScHsp82 proteins and
of 25 mM Tris-HCl (pH 7.5), 50 mM NaCl, 5 mM sodium
phosphate, and 5 mM KCl for PfHsp70-1 and ScSsa1. Assays
were performed using 2.5 μM PfHsp90, PfHsp70-1, ScHsp82,
and ScSsa1 proteins with 30 min preincubation of equimolar
amounts of violacein and DMSO (controls). The values
generated by the CD curves were converted to an ellipticity
molar ratio ([θ]) as follows:
θ θ[ ] =
Cln
100 MM
where [θ] is the mean residual molar ellipticity (in deg cm2/
dmol), MM is the molecular mass of the protein in kDa, C is
the protein concentration (mg/mL), l is the optical path in
cm, and n is the number of amino acid residues of the protein.
4.2.13. Differential Scanning Calorimetry (DSC) for
Chaperone−Violacein Interaction Analysis. DSC was
performed on a Nano DSC (TA Instruments), using the
same buffer as described in section 4.2.12. PfHsp90 and
PfHsp70-1 were exhaustively dialyzed and prepared to a
concentration of 1.0−1.4 mg/mL. The thermal range used for
DSC was 20−90 °C, with a temperature rise of 1 °C/min.
The thermograms of the protein, preincubated or not with a
molar concentration five times higher than that of violacein,
were collected by DSC-Run software (TA Instruments) and
data processing was performed using Launch NanoAnalyze
software.
4.2.14. ATPase Activity Assays. The ATPase activity of
both PfHsp90, PfHsp70-1, ScHsp82, and ScSsa1 proteins was
tested under different concentrations of violacein. The tests
with PfHsp90 and ScHsp82 were performed on a 96-well
microplate with 40 mM HEPES buffer (pH 7.5) supple-
mented with 100 mM KCl. Assays with PfHsp70-1 and
ScSsa1 proteins were performed in 50 mM Tris-HCl buffer
(pH 7.5), 25 mM NaCl, and 5 mM KCl. The PfHsp90 (2.0
μM) and PfHsp70-1 (2.5 μM), ScHsp82 (2 μM) and ScSsa1
(2.5 μM) proteins were incubated for 30 min at 25 °C in the
presence of 2 mM MgCl2 under different concentrations of
violacein (0−20 μM). Then, 1 mM ATP was added, and the
mixture was incubated in a water bath for 30 min at 37 °C.
After the reaction, the solutions were incubated with a
PiColorLock Gold kit Phosphate Detection System (Innova
Biosciences) for 30 min at room temperature. In the ATPase
activity assays performed with the proteins PfHsp90 and
yHsp82, geldanamycin (GA) (0−20 μM) was used as a
positive control. Half of the maximum inhibitory concen-
tration (IC50) was obtained by adjusting the dose response
available in the Origin program (Microcal).
To analyze the type of inhibition resulting from violacein
action on PfHsp70-1 and ScSsa1 proteins, kinetic assays of
PfHsp70-1 (2.5 μM) and ScSsa1 (2.5 μM) were performed in
the presence of 2 mM MgCl2, increasing ATP concentrations
(0−1.0 mM) and two different violacein concentrations (1
and 5 μM). The reactions were incubated for 30 min at 37 °C
and subsequently treated with PiColorLock for 30 min at 25
°C. A standard curve was generated using increasing known
values of free phosphate to provide an indirect data that
correlates color and Pi concentration. After incubation,
experimental readings were made in a Varioskan TM LUX
multimode microplate reader (Thermo Fisher Scientific), with
absorbance measurements in a range of 590−650 nm
wavelength.
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4.2.15. Intrinsic Chaperone Activity Assays. The intrinsic
chaperone activities of PfHsp90, PfHsp70-1, ScHsp82, and
ScSsa1 proteins were tested as previously described84 to
determine the ability to prevent thermal induced aggregation
of the model client protein malate dehydrogenase (MDH)
(porcine heart; Sigma; M2634). The ability of the two
chaperones to avoid protein aggregation was assessed in the
presence or absence of violacein and for the PfHsp90 and
yHsp82 proteins using additionally assays with GA as positive
control. In this test, 1 μM MDH was subjected to a thermal
stress of 42 °C for 3 h, in the absence or presence of
PfHsp90, PfHsp70-1, ScHsp82, and ScSsa1 chaperones,
pretreated or not with an equimolar dose of violacein for 30
min, and in the case of the PfHsp90 and yHsp82 using an
equimolar dose of GA for 30 min. The experimental
procedure was performed in 96-well plates and protein
aggregation was measured by the readings of the light
scattering signal at 320 nm in a Varioskan TM LUX
multimode microplate reader (Thermo Fisher Scientific). All
experiments were performed in the same buffer as that
described in section 4.2.12. Experiments performed solely in
the presence of MDH were used as controls, to determine the
rate of aggregation of this protein in the absence of
chaperones. The effect of violacein on the model protein
thermal aggregation was also evaluated as a control.
4.3. Statistical Analysis. Statistical analysis was per-
formed using Graphpad Prism software version 5.01. Sample
sizes are described in figure legends. To calculate the EC50 in
parasites, a nonlinear regression curve was made with the data
of the parasite survival in relation to control (percentage) and
compound/drug concentration data expressed in logarithmic
scale. For the membrane feeding assay, infection rates between
groups were compared by one-way ANOVA and Kruskal−
Wallis post-test. Data were considered statistically significant
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Plasmodium TRiC-Θ knockdown assay (Figure S1).
Violacein activity against Plasmodium in different stages
(Table S1). Analysis of the primary structure of the
PfHsp70-1 and ScSsa1 proteins (Figure S2). ATPase
activity of PfHsp70-1 and ScSsa11 proteins in the
presence of violacein (Figure S3). PfHsp90 and
PfHsp70-1 thermal stability assays under violacein
treatment (Table S2). MDH aggregation in the
presence of Hsp70 chaperones and violacein (Table
S3). Western blotting against p-eIF2α (Figure S4)
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(35) Capela, R., Magalhaẽs, J., Miranda, D., Machado, M., Sanches-
Vaz, M., Albuquerque, I. S., Sharma, M., Gut, J., Rosenthal, P. J.,
Frade, R., Perry, M. J., Moreira, R., M. Pruden̂cio, F. L., et al. (2018)
Endoperoxide-8-Aminoquinoline Hybrids as Dual-Stage Antimalarial
Agents with Enhanced Metabolic Stability. Eur. J. Med. Chem. 149
(149), 69−78.
(36) Park, E. C., Finley, D., and Szostak, J. W. (1992) A Strategy
for the Generation of Conditional Mutations by Protein Destabiliza-
tion. Proc. Natl. Acad. Sci. U. S. A. 89 (4), 1249−1252.
(37) Parsons, A. B., Brost, R. L., Ding, H., Li, Z., Zhang, C., Sheikh,
B., Brown, G. W., Kane, P. M., Hughes, T. R., and Boone, C. (2004)
Integration of Chemical-Genetic and Genetic Interaction Data Links
Bioactive Compounds to Cellular Target Pathways. Nat. Biotechnol.
22 (1), 62−69.
(38) Giaever, G., Shoemaker, D. D., Jones, T. W., Liang, H.,
Winzeler, E. A., Astromoff, A., and Davis, R. W. (1999) Genomic
Profiling of Drug Sensitivities via Induced Haploinsufficiency. Nat.
Genet. 21 (3), 278−283.
(39) Smith, A. M., Heisler, L. E., St. Onge, R. P., Farias-Hesson, E.,
Wallace, I. M., Bodeau, J., Harris, A. N., Perry, K. M., Giaever, G.,
Pourmand, N., and Nislow, C. (2010) Highly-Multiplexed Barcode
ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article
https://dx.doi.org/10.1021/acsinfecdis.0c00454
ACS Infect. Dis. 2021, 7, 759−776
774
Sequencing: An Efficient Method for Parallel Analysis of Pooled
Samples. Nucleic Acids Res. 38 (13), e142.
(40) Hoepfner, D., McNamara, C. W., Lim, C. S., Studer, C., Riedl,
R., Aust, T., McCormack, S. L., Plouffe, D. M., Meister, S., Schuierer,
S., Plikat, U., Hartmann, N., Staedtler, F., Cotesta, S., Schmitt, E. K.,
Petersen, F., Supek, F., Glynne, R. J., Tallarico, J. A., Porter, J. A.,
Fishman, M. C., Bodenreider, C., Diagana, T. T., Movva, N. R., and
Winzeler, E. A. (2012) Selective and Specific Inhibition of the
Plasmodium Falciparum Lysyl-TRNA Synthetase by the Fungal
Secondary Metabolite Cladosporin. Cell Host Microbe 11 (6), 654−
663.
(41) Rodger, A., Marrington, R., Roper, D., and Windsor, S. (2005)
Circular Dichroism Spectroscopy for the Study of Protein-Ligand
Interactions. Methods Mol. Biol. 305, 343−363.
(42) Zsila, F. (2013) Circular Dichroism Spectroscopic Detection
of Ligand Binding Induced Subdomain IB Speci Fi c Structural
Adjustment of Human Serum Albumin. J. Phys. Chem. B 117 (37),
10798−10806.
(43) Minari, K., de Azevedo, E. C., Kiraly, V. T. R., Batista, F. A. H.,
de Moraes, F. R., de Melo, F. A., Nascimento, A. S., Gava, L. M.,
Ramos, C. H. I., and Borges, J. C. (2019) Thermodynamic Analysis
of Interactions of the Hsp90 with Adenosine Nucleotides: A
Comparative Perspective. Int. J. Biol. Macromol. 130, 125−138.
(44) Silva, K. P., Seraphim, T. V., and Borges, J. C. (2013)
Structural and Functional Studies of Leishmania Braziliensis Hsp90.
Biochim. Biophys. Acta, Proteins Proteomics 1834 (1), 351−361.
(45) Montgomery, D. L., Morimoto, R. I., and Gierasch, L. M.
(1999) Mutations in the Substrate Binding Domain of the
Escherichia Coli 70 KDa Molecular Chaperone, DnaK, Which
Alter Substrate Affinity or Interdomain Coupling. J. Mol. Biol. 286
(3), 915−932.
(46) Batinovic, S., McHugh, E., Chisholm, S. A., Matthews, K., Liu,
B., Dumont, L., Charnaud, S. C., Schneider, M. P., Gilson, P. R., De
Koning-Ward, T. F., Dixon, M. W. A., and Tilley, L. (2017) An
Exported Protein-Interacting Complex Involved in the Trafficking of
Virulence Determinants in Plasmodium-Infected Erythrocytes. Nat.
Commun. 8 (1), 16044.
(47) Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper,
P. W., and Pearl, L. H. (1999) Structural Basis for Inhibition of the
Hsp90 Molecular Chaperone by the Antitumor Antibiotics Radicicol
and Geldanamycin. J. Med. Chem. 42 (2), 260−266.
(48) Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl,
F. U., and Pavletich, N. P. (1997) Crystal Structure of an Hsp90 -
Geldanamycin Complex: Targeting of a Protein Chaperone by an
Antitumor Agent. Cell 89 (2), 239−250.
(49) Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E.,
and Neckers, L. M. (1994) Inhibition of Heat Shock Protein HSP90-
Pp6Ov-Src Heteroprotein Complex Formation by Benzoquinone
Ansamycins: Essential Role for Stress Proteins in Oncogenic
Transformation. Proc. Natl. Acad. Sci. U. S. A. 91 (18), 8324−8328.
(50) Li, J., Soroka, J., and Buchner, J. (2012) The Hsp90
Chaperone Machinery: Conformational Dynamics and Regulation
by Co-Chaperones. Biochim. Biophys. Acta, Mol. Cell Res. 1823, 624−
635.
(51) Silva, K. P., and Borges, J. C. (2011) The Molecular
Chaperone Hsp70 Family Members Function by a Bidirec- Tional
Heterotrophic Allosteric Mechanism. Protein Pept. Lett. 18 (2), 132−
142.
(52) Young, J. C. (2010) Mechanisms of the Hsp70 Chaperone
System. Biochem. Cell Biol. 88 (2), 291−300.
(53) Clerico, E. M., Tilitsky, J. M., Meng, W., and Gierasch, L. M.
(2015) How Hsp70 Molecular Machines Interact with Their
Substrates to Mediate Diverse Physiological Functions. J. Mol. Biol.
427 (7), 1575−1588.
(54) Kityk, R., Kopp, J., Sinning, I., and Mayer, M. P. (2012)
Structure and Dynamics of the ATP-Bound Open Conformation of
Hsp70 Chaperones. Mol. Cell 48 (6), 863−874.
(55) Liberek, K., Lewandowska, A., and Zietkiewicz, S. (2008)
Chaperones in Control of Protein Disaggregation. EMBO J. 27 (2),
328−335.
(56) Silva, K. P., Seraphim, T. V., and Borges, J. C. (2013)
Structural and Functional Studies of Leishmania Braziliensis Hsp90.
Biochim. Biophys. Acta, Proteins Proteomics 1834 (1), 351−361.
(57) Kravats, A. N., Hoskins, J. R., Reidy, M., Johnson, J. L., Doyle,
S. M., Genest, O., Masison, D. C., and Wickner, S. (2018) Functional
and Physical Interaction between Yeast Hsp90 and Hsp70. Proc. Natl.
Acad. Sci. U. S. A. 115 (10), E2210−E2219.
(58) Leu, J. I., Pimkina, J., Pandey, P., Murphy, M. E., and George,
D. L. (2011) HSP70 Inhibition by the Small-Molecule 2-Phenyl-
ethynesulfonamide Impairs Protein Clearance Pathways in Tumor
Cells. Mol. Cancer Res. 9 (7), 936−948.
(59) Leu, J. I-J., Pimkina, J., Frank, A., Murphy, M. E., and George,
D. L. (2009) A Small Molecule Inhibitor of Inducible Heat Shock
Protein 70 (HSP70). Mol. Cell 36 (1), 15−27.
(60) Galluzzi, L., Diotallevi, A., and Magnani, M. (2017)
Endoplasmic Reticulum Stress and Unfolded Protein Response in
Infection by Intracellular Parasites. Futur. Sci. OA 3 (3), FSO198.
(61) Bridgford, J. L., Xie, S. C., Cobbold, S. A., Pasaje, C. F. A.,
Herrmann, S., Yang, T., Gillett, D. L., Dick, L. R., Ralph, S. A.,
Spillman, N. J., Tilley, L., and Dogovski, C. (2018) Artemisinin Kills
Malaria Parasites by Damaging Proteins and Inhibiting the
Proteasome. Nat. Commun. 9, 3801.
(62) Xie, S. C., Gillett, D. L., Spillman, N. J., Tsu, C., Luth, M. R.,
Ottilie, S., Duffy, S., Gould, A. E., Hales, P., Seager, B. A., Charron,
C. L., Bruzzese, F., Yang, X., Zhao, X., Huang, S.-C., Hutton, C. A.,
Burrows, J. N., Winzeler, E. A., Avery, V. M., Dick, L. R., and Tilley,
L. (2018) Target Validation and Identi Fi Cation of Novel Boronate
Inhibitors of the Plasmodium Falciparum Proteasome. J. Med. Chem.
61 (22), 10053−10066.
(63) Buchberger, A., Bukau, B., and Sommer, T. (2010) Protein
Quality Control in the Cytosol and the Endoplasmic Reticulum:
Brothers in Arms. Mol. Cell 40 (2), 238−252.
(64) Antonova-Koch, Y., Meister, S., Abraham, M., Luth, M. R.,
Ottilie, S., Lukens, A. K., Sakata-Kato, T., Vanaerschot, M., Owen, E.,
Jado Rodriguez, J. C., Maher, S. P., Calla, J., Plouffe, D., Zhong, Y.,
Chen, K., Chaumeau, V., Conway, A. J., McNamara, C. W., Ibanez,
M., Gagaring, K., Serrano, F. N., Eribez, K., Taggard, C. M. L.,
Cheung, A. L., Lincoln, C., Ambachew, B., Rouillier, M., Siegel, D.,
Nosten, F., Kyle, D. E., Gamo, F. J., Zhou, Y., Llinás, M., Fidock, D.
A., Wirth, D. F., Burrows, J., Campo, B., and Winzeler, E. A. (2018)
Open-Source Discovery of Chemical Leads for next-Generation
Chemoprotective Antimalarials. Science 362 (6419), eaat9446.
(65) Bermud́ez, M., Andrés, D., Pérez, M., Pinzón, G. A., Curtidor,
H., and Patarroyo, M. A. (2018) Plasmodium Vivax in Vitro
Continuous Culture: The Spoke in the Wheel. Malar. J., 1−12.
(66) Bousema, T., and Drakeley, C. (2011) Epidemiology and
Infectivity of Plasmodium Falciparum and Plasmodium Vivax
Gametocytes in Relation to Malaria Control and Elimination. Clin.
Microbiol. Rev. 24 (2), 377−410.
(67) Moran Luengo, T., Mayer, M. P., and Rudiger, S. G.D. (2019)
The Hsp70 - Hsp90 Chaperone Cascade in Protein Folding. Trends
Cell Biol. 29 (2), 164−177.
(68) Wilkinson, M. D., Lai, H.-E., Freemont, P. S., and Baum, J.
(2020) A Biosynthetic Platform for Antimalarial Drug Discovery.
Antimicrob. Agents Chemother., DOI: 10.1128/AAC.02129-19.
(69) Neckers, L., and Workman, P. (2012) Hsp90 Molecular
Chaperone Inhibitors: Are We There Yet? Clin. Cancer Res. 18 (1),
64−76.
(70) Gestwicki, J. E., and Shao, H. (2019) Inhibitors and Chemical
Probes for Molecular Chaperone Networks. J. Biol. Chem. 294 (6),
2151−2161.
(71) Trager, W., and Jensen, J. B. (1976) Human Malaria Parasites
in Continuous Culture. Science (Washington, DC, U. S.) 193 (4254),
673−675.
(72) Ploemen, I. H., Pruden̂cio, M., Douradinha, B. G., Ramesar, J.,
Fonager, J., van Gemert, G. J., Luty, A. J., Hermsen, C. C., Sauerwein,
ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article
https://dx.doi.org/10.1021/acsinfecdis.0c00454
ACS Infect. Dis. 2021, 7, 759−776
775
R. W., Baptista, F. G., Mota, M. M., Waters, A. P., Que, I., Lowik, C.
W., Khan, S. M., C.J. Janse, B. M. F.-F., et al. (2009) Visualization
and Quantitative Analysis of the Rodent Malaria Liver Stage by Real
Time Imaging. PLoS One 4 (11), No. e7881.
(73) Pimenta, P. F. P., Orfano, A. S., Bahia, A. C., Duarte, A. P. M.,
Ríos-Velásquez, C. M., Melo, F. F., Pessoa, F. A. C., Oliveira, G. A.,
Campos, K. M. M., Villegas, L. M., Rodrigues, N. B., Nacif-pimenta,
R., Simões, R. C., Monteiro, W. M., Amino, R., Traub-cseko, Y. M.,
Lima, J. B. P., Barbosa, M. G. V, Lacerda, M. V. G., Tadei, W. P., and
Secundino, N. F. C. (2015) An Overview of Malaria Transmission
from the Perspective of Amazon Anopheles Vectors. Mem. Inst.
Oswaldo Cruz 110 (1), 23−47.
(74) Hartwig, C. L. et al. (2013) BYBR Green I-Based Parasite
Growth Inhibition Assay for Measurement of Antimalarial Drug
Susceptibility in Plasmodium Falciparum. Methods in Malaria
Research, pp 122−129.
(75) Dearnley, M. K., Yeoman, J. A., Hanssen, E., Kenny, S.,
Turnbull, L., Whitchurch, C. B., Tilley, L., and Dixon, M. W. A.
(2012) Origin, Composition, Organization and Function of the Inner
Membrane Complex of Plasmodium Falciparum Gametocytes. J. Cell
Sci. 125 (8), 2053−2063.
(76) Dixon, M. W. A., Dearnley, M. K., Hanssen, E., Gilberger, T.,
and Tilley, L. (2012) Shape-Shifting Gametocytes: How and Why
Does P. Falciparum Go Banana-Shaped ? Trends Parasitol. 28 (11),
471−478.
(77) Schneekloth, J. S., Fonseca, F. N., Koldobskiy, M., Mandal, A.,
Deshaies, R., Sakamoto, K., and Crews, C. M. (2004) Chemical
Genetic Control of Protein Levels: Selective in Vivo Targeted
Degradation. J. Am. Chem. Soc. 126 (12), 3748−3754.
(78) Magariños, M. P., Carmona, S. J., Crowther, G. J., Ralph, S. A.,
Roos, D. S., Shanmugam, D., Van Voorhis, W. C., and Agüero, F.
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